A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis

Qiong Pan, Gang Luo, Jiaquan Qu, Sheng Chen, Xiaoxun Zhang, Nan Zhao, Jingjing Ding, Hong Yang, Mingqiao Li, Ling Li, Ying Cheng, Xuan Li, Qiaoling Xie, Qiao Li, Xueqian Zhou, Huiling Zou, Shijun Fan, Lingyun Zou, Wei Liu, Guohong Deng, Shi‐Ying Cai, James L. Boyer, Jin ChaiEMBO 2021 · DOI

TL;DR

This study identifies a novel genetic cause of progressive familial intrahepatic cholestasis (PFIC) linked to a homozygous mutation (R148W) in the Semaphorin 7A (SEMA7A) gene. The research demonstrates that this mutation impairs bile acid transport in the liver, leading to cholestasis, and shows that a combination therapy of UDCA and GSH can improve liver function in affected individuals.

What Problem Does This Paper Address?

Progressive familial intrahepatic cholestasis (PFIC) is a group of rare genetic disorders characterized by impaired bile flow from the liver, leading to liver damage and potentially liver failure. While several genes involved in bile formation and transport have been linked to PFIC, the genetic landscape of this disease is not fully understood, meaning some cases remain undiagnosed. This paper addresses the challenge of identifying the genetic basis of PFIC in a patient with unexplained liver dysfunction, specifically investigating SEMA7A as a potential candidate gene.

Methods

The researchers employed a multi-pronged approach:

  • Whole-Genome Sequencing (WGS): This was the primary tool for identifying genetic variants in the patient and her family. They used a recessive inheritance model to filter potential causative mutations.
  • Sanger Sequencing: Used to confirm the WGS findings for specific candidate mutations.
  • Mouse Models: Sema7a and Slc10a1 knockout/mutant mouse models were generated to investigate the functional consequences of identified mutations in vivo. This is a standard approach for studying gene function in disease.
  • Biochemical Assays: Serum levels of liver enzymes (ALT, AST) and total bile acids (TBA) were measured to assess liver function in both the patient and the mouse models.
  • Histology: Liver tissue from mice was examined to identify pathological changes, such as hydropic degeneration.
  • LC-MS/MS (Liquid Chromatography-Mass Spectrometry): Used to quantify bile acid levels in liver tissue.
  • Western Blotting and Multiplex Immunofluorescence (IF): These techniques were used to assess the expression levels of key bile acid transporters (BSEP, MRP2) in liver tissue and primary hepatocytes.
  • Cell Culture Experiments: Primary mouse hepatocytes and human hepatoma HepG2 cells were transfected with wild-type and mutant SEMA7A constructs to study the direct impact of the mutation on transporter expression.

Datasets

  • Human Patient Data: Clinical data, serum biochemistry, and whole-genome sequencing data from a single patient and her family.
  • Mouse Model Data: Biochemical, histological, and molecular data from wild-type, heterozygous, and homozygous Sema7a and Slc10a1 mutant mice.
  • Public Databases: WGS data was filtered against public databases like 1000 Genomes, ExAC, and ESP6500 for allele frequencies.

Key Insights and Ideas

  • SEMA7A as a Novel PFIC Gene: The most significant insight is the identification of SEMA7A as a new player in progressive familial intrahepatic cholestasis. This expands the known genetic causes of this severe liver disease.
  • R148W Mutation Disrupts Bile Acid Transport: The study provides strong evidence that the R148W mutation in SEMA7A directly impairs the function of crucial bile acid transporters (BSEP and MRP2) in the liver. This is a critical mechanistic link between the genetic defect and the observed cholestasis.
  • Post-Translational Regulation is Key: Interestingly, the mRNA levels of BSEP and MRP2 were not significantly reduced in mutant mice, but their protein levels were. This suggests that the SEMA7A mutation affects the stability or trafficking of these transporters at the protein level, likely through post-translational modifications.
  • Therapeutic Potential of UDCA and GSH: The successful improvement of liver function in the patient with UDCA and GSH highlights a potential therapeutic strategy for this specific type of PFIC, offering hope for affected individuals.

Key Results

  • A female infant presented with elevated ALT, AST, and TBA, with no other known cause identified.
  • WGS revealed a homozygous R148W mutation in SEMA7A in the patient.
  • Sema7a<sup>R145W</sup> homozygous mice exhibited elevated serum ALT, AST, and TBA, along with hepatocyte hydropic degeneration, mimicking the patient's phenotype.
  • In Sema7a<sup>R145W</sup> homozygous mice, hepatic levels of BSEP and MRP2 protein expression were significantly reduced, while mRNA levels remained largely unchanged.
  • In vitro studies showed that overexpressing the mutant SEMA7A<sup>R148W</sup> protein in hepatocytes led to a greater reduction in BSEP and MRP2 protein levels compared to wild-type SEMA7A.
  • Administration of UDCA and GSH to the patient significantly improved liver function tests, which relapsed upon cessation of treatment.

Limitations and Future Work

  • Single Patient Case: The study is based on a single patient, which limits the generalizability of the findings. Further identification and characterization of patients with SEMA7A mutations are needed.
  • Pruritus Absence: The patient did not exhibit pruritus, a common symptom in other PFIC types. The authors suggest that additional patients need to be identified to determine if pruritus is associated with this new PFIC subtype.
  • Detailed Mechanistic Elucidation: While the study points to reduced BSEP and MRP2 expression, the precise molecular cascade by which SEMA7A<sup>R148W</sup> leads to this reduction (e.g., specific signaling pathways, protein degradation mechanisms) requires further investigation. The authors hint at PKC activation as a potential mediator.
  • SLC10A1<sup>S267F</sup> Allele: The patient also carried an SLC10A1<sup>S267F</sup> allele. While Slc10a1<sup>S267F</sup> homozygous mice showed normal liver function, the potential additive or synergistic effect of this allele with the SEMA7A mutation in humans warrants further consideration.
  • Long-term Treatment Efficacy: While UDCA and GSH showed short-term benefits, long-term efficacy and optimal dosing require further study.

Summary updated

Abstract

Semaphorin 7A (SEMA7A) is a membrane-bound protein that involves axon growth and other biological processes. SEMA7A mutations are associated with vertebral fracture and Kallmann syndrome. Here, we report a case with a mutation in SEMA7A that displays familial cholestasis. WGS reveals a SEMA7A<sup>R148W</sup> homozygous mutation in a female child with elevated levels of serum ALT, AST, and total bile acid (TBA) of unknown etiology. This patient also carried a SLC10A1<sup>S267F</sup> allele, but Slc10a1<sup>S267F</sup> homozygous mice exhibited normal liver function. Similar to the child, Sema7a<sup>R145W</sup> homozygous mice displayed elevated levels of serum ALT, AST, and TBA. Remarkably, liver histology and LC-MS/MS analyses exhibited hepatocyte hydropic degeneration and increased liver bile acid (BA) levels in Sema7a<sup>R145W</sup> homozygous mice. Further mechanistic studies demonstrated that Sema7a<sup>R145W</sup> mutation reduced the expression of canalicular membrane BA transporters, bile salt export pump (Bsep), and multidrug resistance-associated protein-2 (Mrp2), causing intrahepatic cholestasis in mice. Administration with ursodeoxycholic acid and a dietary supplement glutathione improved liver function in the child. Therefore, Sema7a<sup>R145W</sup> homozygous mutation causes intrahepatic cholestasis by reducing hepatic Bsep and Mrp2 expression.
BibTeX
@inproceedings{pan2021homozygous,
  author = {Qiong Pan and Gang Luo and Jiaquan Qu and Sheng Chen and Xiaoxun Zhang and Nan Zhao and Jingjing Ding and Hong Yang and Mingqiao Li and Ling Li and Ying Cheng and Xuan Li and Qiaoling Xie and Qiao Li and Xueqian Zhou and Huiling Zou and Shijun Fan and Lingyun Zou and Wei Liu and Guohong Deng and Shi‐Ying Cai and James L. Boyer and Jin Chai},
  title = {{A homozygous R148W mutation in <i>Semaphorin 7A</i> causes progressive familial intrahepatic cholestasis}},
  booktitle = {EMBO},
  year = {2021},
  doi = {10.15252/emmm.202114563},
}
Figure